LambdaVision is a pioneering brand that is dedicated to designing and developing an innovative, protein-based artificial retina. They aim to restore functional vision to individuals who would otherwise be blind due to retinal degenerative diseases, such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Currently, there is no cure for these diseases, and available treatments only slow down their progression.

LambdaVision's artificial retina utilizes a light-activated protein called bacteriorhodopsin to help patients regain their vision and carry out everyday tasks independently. The brand was founded by a group of researchers led by Dr. Robert R.

Birge, a renowned professor of chemistry at UConn and a pioneer in the field of light-sensitive proteins. The company's leadership team, headed by Dr. Nicole L.

Wagner as the President and Chief Executive Officer, is committed to securing funding and accelerating the research, development, and commercialization of LambdaVision's artificial retina. With a strong focus on innovation and cutting-edge technology, LambdaVision is dedicated to providing a meaningful solution to the significant unmet need in restoring vision for those affected by retinal degenerative diseases